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White adipose tissue (WAT) dysfunction plays a key
role in the pathogenesis of type 2 diabetes (DM2).
Unrestrained WAT lipolysis results in increased fatty
acid release, leading to insulin resistance and
lipotoxicity, while impaired de novo lipogenesis in
WAT decreases the synthesis of insulin-sensitizing
fatty acid species like palmitoleate. Here, we show
that insulin infused into the mediobasal hypothal-
amus (MBH) of Sprague-Dawley rats increases
WAT lipogenic protein expression, inactivates
hormone-sensitive lipase (Hsl), and suppresses
lipolysis. Conversely, mice that lack the neuronal
insulin receptor exhibit unrestrained lipolysis and
decreased de novo lipogenesis in WAT. Thus, brain
and, in particular, hypothalamic insulin action play
a pivotal role in WAT functionality.
INTRODUCTION
Adipose tissue functionality plays a critical role in normal glucose
and lipid homeostasis. One of the major functions of white
adipose tissue (WAT) is the release of nonesterified fatty acids
(NEFAs) into the circulation during fasting and other energy-
demanding states, such as exercise. Unrestrained lipolysis,
which leads to increased circulating fatty acids in the absorptive
state, has been linked to muscle (Bergman and Ader, 2000;
Boden, 2006) and liver (Boden et al., 1994) insulin resistance
as well as hepatic steatosis (Ginsberg et al., 2006). Total fatty
acid flux increases with adiposity, consistent with unrestrained
lipolysis (Mittendorfer et al., 2009). Recently, it has been demon-
strated that the insulin-sensitizing fatty acid palmitoleate, termed
a lipokine, is mainly produced in WAT via de novo lipogenesis
(Cao et al., 2008). In obese humans, there is evidence forCell MreducedWAT de novo lipogenesis (Diraison et al., 2002; Roberts
et al., 2009), which further supports the concept that WAT repre-
sents a key link between obesity and the insulin-resistant state.
However, the pathogenesis of adipose tissue dysfunction is still
poorly understood.
Humans with insulin receptor mutations exhibit severe
lipodystrophy and elevated circulating fatty acids, which high-
lights the pivotal role that insulin signaling plays in the mainte-
nance of WAT functionality (Hegele, 2003). Insulin is considered
the major antilipolytic hormone. Its antilipolytic effects are
thought to be exclusively mediated through insulin receptors ex-
pressed on adipocytes (Degerman et al., 2003). Cyclic AMP
(cAMP) signaling represents the principal prolipolytic pathway
in WAT, which is chiefly regulated by the sympathetic nervous
system (SNS). However, it is presently unknown whether insulin
regulates WAT lipolysis by inhibiting sympathetic outflow
through brain effects, and if so, in which anatomical brain struc-
ture. The proposition that insulin action in the brain could regu-
late WAT lipolysis is supported by the finding that deletion of
the murine insulin receptors in both the brain and periphery
results in severe lipodystrophy, yet deletion of insulin receptors
in peripheral tissues (including WAT) alone but not the
brain leads to only mild changes in adiposity (Koch et al.,
2008). Therefore, we hypothesized that insulin acts in the brain
to suppress lipolysis and induce lipogenesis, maintaining
adipose functionality.
RESULTS
To test whether brain, and specifically hypothalamic insulin
signaling, regulates WAT lipolysis and lipogenesis, we raised
insulin levels locally in the brain by infusing insulin directly into
the third ventricle (intracerebroventricularly, or i.c.v.) or themedi-
obasal hypothalamus (MBH) of male Sprague-Dawley (SD) rats
via stereotactic cannulae. To first delineate insulin signaling in
specific hypothalamic nuclei within the MBH, we performed
acute insulin signaling studies in i.c.v. and MBH insulin-infusedetabolism 13, 183–194, February 2, 2011 ª2011 Elsevier Inc. 183
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Figure 1. Brain Insulin Suppresses Whole-Body Lipolysis
(A) Experimental protocol of the euglycemic clamp studies of SD rats. i.c.v. or MBH insulin infusions were performed during basal insulin clamps
(1 mU $ kg1 $ min1) and compared to rats subjected to hyperinsulinemic clamps (3 mU $ kg1 $ min1), while glycerol and glucose fluxes were determined
through tracer dilution techniques.
(B and C) Ra glycerol during basal (B) and clamped (C) conditions (nR 3 per group).
(D) Change of plasma NEFA levels compared to baseline during the 6 hr infusion protocol. Arrowhead marks the start of the clamp at time point 120 min (nR 4
per group).
(E) AUC of Figure 1D comparing vehicle to i.c.v. and MBH insulin-infused rats prior to the start of the clamp study (time point from 120 to 120 min, n R 4
per group).
(F) Plasma insulin levels during baseline (time point from 120 to 120 min preclamp period) and the clamp (from 120 to 240 min, nR 6 per group).
(G–I) Plasma glucagon, leptin, and adiponectin levels of MBH vehicle- and insulin-infused rats at baseline and the clamp (nR 6). All error bars are SEM; *p < 0.05,
**p < 0.01, ***p < 0.001 versus vehicle + 1 mU $ kg1 $min1 clamp group if not otherwise indicated. #p < 0.05 versus vehicle + 3 mU $ kg1 $min1 clamp group
(see also Figure S1).
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Brain Insulin Controls Adipose Tissue Functionrats and analyzed punch biopsies of the arcuate nucleus (ARC)
and the ventromedial hypothalamus (VMH) by western blot at
doses that have been commonly used by others (Carvalheira
et al., 2003; Rahmouni et al., 2004; Roman et al., 2005). Brain
insulin infusion increased insulin receptor phosphorylation and
activated downstream targets such as Akt, glycogen synthase
kinase 3 (Gsk3), and extracellular signal-regulated kinase (ERK)
1/2 predominantly in the ARC compared to the VMH (Figures
S1A and S1B). Next, we infused insulin i.c.v. or intraparenchy-
mally into theMBH for a 6 hr time period to study the role of brain
insulin in the regulation of lipolysis in vivo. To reduce the
likelihood of pharmacological effects of the insulin doses admin-
istered, we chose a dose of insulin that is more than 15,000-fold
lower than those commonly used for i.c.v. insulin infusions
(Air et al., 2002; Brief and Davis, 1984; Rahmouni et al., 2004).
Since the intracerebral infusion of hormones can alter pancreatic
insulin secretion and circulating glucose levels, we subjected184 Cell Metabolism 13, 183–194, February 2, 2011 ª2011 Elsevier Inthe animals to pancreatic clamps (protocol depicted in Fig-
ure 1A) to maintain euglycemia during the brain infusion of
insulin or artificial cerebrospinal fluid (vehicle) (Figure S1C). To
compare the effects of isolated brain insulin signaling with
the effects of systemic insulin (which includes the direct effects
of insulin on adipocytes), we either kept plasma insulin at
baseline levels (1 mU $ kg1 $ min1) or induced hyperinsuline-
mia (3 mU $ kg1 $ min1) to mimic the fed state (Figure 1F).
As glucose metabolism and lipolysis are regulated by insulin,
both were assessed simultaneously by employing tracer dilution
techniques to determine glucose and glycerol fluxes utilizing
[3-3H]glucose and [2H-5]glycerol, respectively.
Brain Insulin Suppresses Whole-Body Lipolysis
Both i.c.v. and MBH insulin administration markedly suppressed
the rate of appearance (Ra) of glycerol under basal and clamped
conditions, indicating that brain insulin, and more specificallyc.
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Figure 2. MBH Insulin Suppresses Hepatic
GP, which Correlates with Lipolytic Flux
(A) GIR required to maintain euglycemia. Right,
AUC of line graph on the left (nR 6 per group).
(B) Baseline hepatic GP (nR 6 per group).
(C) Clamp hepatic GP (nR 6 per group).
(D) Percent suppression of GP during the clamp
from baseline (nR 6 per group).
(E) Rate of glucose disposal during the clamp (nR
6 per group).
(F) Correlation between Ra glycerol and hepatic
GP during the 1 mU clamp (n = 11). All error bars
are SEM; *p < 0.05, **p < 0.01, ***p < 0.001 versus
vehicle + 1 mU $ kg1 $ min1 clamp group (see
also Figure S2).
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Brain Insulin Controls Adipose Tissue FunctionMBH insulin signaling, suppresses lipolysis (Figures 1B and 1C).
Systemic glucose and insulin levels were not different between
i.c.v. vehicle-, i.c.v. insulin-, and MBH insulin-infused rats during
a 1 mU $ kg1 $ min1 basal pancreatic clamp, while insulin
levels were raised about 3-fold in the 3 mU $ kg1 $min1 hyper-
insulinemic clamp group (Figures S1C and S1F). Thus,
brain insulin infusion inhibited lipolysis independently of
increases in peripheral insulin levels. Hyperinsulinemia induced
by a 3 mU $ kg1 $ min1 clamp decreased the Ra glycerol by
about 65% compared to a 1 mU $ kg1 $ min1 clamp in
vehicle-infused animals (Figure 1C). Thus, at the doses adminis-
tered, brain insulin infusion inhibited lipolysis to an extent similar
to that achieved with peripheral hyperinsulinemia. In a separate
series of studies, we repeated MBH insulin infusions and
compared this to MBH vehicle-infused animals. Again, MBH
insulin markedly suppressed Ra glycerol compared to MBH
vehicle-infused rats independently of circulating glucose and
insulin levels (Figures S2A, S2D, and S2E).
These dynamic changes in the rates of whole-body lipolysis
were reflected by changes in static measurements of plasma
parameters of fatty acid metabolism, albeit to a lesser degree.
NEFA levels trended to increase during the basal clamp periodCell Metabolism 13, 183–194in vehicle-infused animals, which is due
to the transitioning of the animal into the
fasting state and the flushing of catheters
with saline and heparin, a lipoprotein
lipase activator, commonly used to
prevent clotting of the vascular access.
This rise in plasma NEFA levels was pre-
vented by both MBH and i.c.v. insulin
administration (Figure 1D), which was
also reflected in a significantly lower
AUC (Figure 1E). Of note, the effects of
centrally administered insulin closely
mimicked the effects of systemic insulin
infusion in humans, where the heparin-
induced increase in plasma NEFAs is
completely blunted by insulin treatment
(Chaudhuri et al., 2007). Plasma glycerol
and triglyceride levels trended in the
same direction, although this failed to
reach statistical significance (Figures
S1D and S1E). As expected, due to theadministration of somatostatin, glucagon levels decreased
during the clamp, but neither glucagon nor the levels of the
adipokines leptin and adiponectin were different between
groups (Figures 1G–1I).
Lipolytic Flux Tightly Correlates with Hepatic
Glucose Production
Lipolytic flux can potentially regulate hepatic glucose production
(GP) through two mechanisms (Mittelman and Bergman, 2000;
Rebrin et al., 1996): (1) by providing the liver with the gluconeo-
genic precursor glycerol and (2) by enabling the synthesis of
high-energy NADH substrates required during gluconeogenesis
through b-oxidation of NEFAs (Hers and Hue, 1983). Therefore,
we simultaneously assessed glucose fluxes in the same studies
to uncover a potential interdependence. MBH insulin-infused
rats required higher glucose infusion rates (GIRs) compared to
vehicle-infused rats during the clamp (Figures 2A and S2F) and
suppressed hepatic GP to an extent similar to rats treated with
systemic hyperinsulinemia (Figures 2C, 2D, and S2B), which is
consistent with prior reports (Pocai et al., 2005). Notably, despite
the ability of MBH insulin to suppress hepatic GP during the
clamp period, circulating glucose levels (Figures S1C and S2D), February 2, 2011 ª2011 Elsevier Inc. 185
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Figure 3. MBH Insulin Suppresses Hsl Acti-
vation and Increases Lipogenic Protein
Expression
(A and B) MBH insulin suppresses lipolysis and
induces lipogenesis in WAT. Left, representative
western blot analyses of epidydimal fat pads
from clamped animals. Right, quantification of
the western blot analyses (nR 5 per group).
(C) Lipid-droplet-depleted cytosolic triglyceride
hydrolase activity (n R 8 per group; one-tailed
t test was applied).
(D) FAS activity measured in perirenal fat depots
(n = 4 per group; one-tailed t test was applied).
All error bars are SEM; *p < 0.05 vehicle group
(see also Figure S3).
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Brain Insulin Controls Adipose Tissue Functionand hepatic GP (Figure 2B) did not change during the basal
period where MBH insulin was infused, but not IV somatostatin.
Glucose disposal into peripheral tissues, as assessed through
the use of [3-3H]glucose tracer dilution technique, was not
altered by central insulin infusion during basal clamps (Figures
2E and S2C). As expected, systemic hyperinsulinemia increased
glucose utilization in peripheral tissues like muscle and WAT,
which is mainly a function of the direct effects of insulin on
both tissues (Figure 2E). Of note, the Ra glycerol tightly corre-
lated with hepatic GP during the 1 mU clamps (Figure 2F), while
neither of these parameters correlated with circulating insulin
levels (Figures S2H and S2I). Since we controlled glucose levels
through euglycemic clamps, we can rule out that hepatic GP
drives WAT lipolysis in these studies. However, the tight correla-
tion between lipolytic flux and hepatic GP during the MBH insulin
infusion as well as the fact that MBH insulin did not change
hepatic gluconeogenic gene expression of Pck1 and G6pc
(Figure S2G) suggests that one of the mechanisms through
which hypothalamic insulin regulates hepatic GP is by controlling
lipolytic flux from WAT.
MBH Insulin Decreases Systemic Lipolysis
by Decreasing Hsl and Atgl Activation in
WAT by Suppressing Sympathetic Outflow
To delineate the molecular mechanisms through which hypotha-
lamic insulin regulates lipolysis, we analyzed the expression and
activation state of lipolytic proteins such as hormone-sensitive
lipase (Hsl, encoded by Lipe). Hsl hydrolyzes diacylglycerols to186 Cell Metabolism 13, 183–194, February 2, 2011 ª2011 Elsevier Inc.monoacylglycerols and serves as
a marker for SNS outflow to WAT (Bart-
ness et al., 2010; Buettner et al., 2008).
Consistent with the glycerol flux data,
we found that central insulin suppressed
the activation state of Hsl (Figure 3A).
Protein kinase A (PKA) activates Hsl
through phosphorylation of Ser563 and
Ser660 (Anthonsen et al., 1998). Central
insulin decreased phosphorylation at
both these sites, while phosphorylation
of Ser565, which inactivates Hsl (Anthon-
sen et al., 1998), trended to be increased
(Figure 3A). Hsl is phosphorylated atSer565 by AMP-activated protein kinase (Ampk) (Anthonsen
et al., 1998; Garton and Yeaman, 1990), which has been shown
to inhibit adipocyte lipolysis (Anthony et al., 2009). Indeed, phos-
pho-Ampka (Thr172) levels, an indicator of Ampk activation,
were increased in WAT from MBH insulin-infused animals (Fig-
ure S3A). Next, we assessed triglyceride hydrolase activity in
lipid-droplet-depleted adipose tissue homogenates harvested
from the sameMBH insulin- and vehicle-infused rats. The activa-
tion of Hsl by PKA leads to its translocation from the cytosol to
the surface of the lipid droplet (Egan et al., 1992; Granneman
et al., 2007). As total Hsl levels in total cell extracts were not
different between MBH insulin- and vehicle-infused rats (data
not shown), activation of Hsl should lead to its cytosolic deple-
tion. Since MBH insulin infusion suppressed Hsl phosphoryla-
tion, we predicted higher cytosolic Hsl activity compared to
vehicle-infused controls after lipid droplet removal, which indeed
was the case (Figure 3C). Thus, MBH insulin suppresses Hsl
activity in WAT by inhibiting its phosphorylation and thereby
likely its translocation to lipid droplets.
Adipose tissue triglyceride lipase (Atgl, encoded by Pnpla2)
hydrolyzes triacylglycerols to diacylglycerols and, together with
Hsl, accounts for over 90% of the WAT acyl-hydrolase activity
(Zimmermann et al., 2004). MBH insulin infusion did not
alter Atgl protein expression in WAT (Figure 3A). However, Atgl
activity is not solely determined by total protein levels, but is
also regulated through cAMP-dependent and -independent
posttranslational modification. Atgl activity is increased upon
b-adrenergic stimulation via a posttranslational mechanism
Cell Metabolism
Brain Insulin Controls Adipose Tissue Function(Haemmerle et al., 2006). This activation critically depends on
the phosphorylation of the lipid-droplet-associated protein
perilipin, which involves the dissociation of a/b hydrolase domain
containing protein 5 (ABHD5; also known as comparative gene
identification-58 [CGI-58]) from perilipin and its subsequent acti-
vation of Atgl (Granneman et al., 2007; Miyoshi et al., 2007; Zim-
mermann et al., 2009). Phospho-perilipin, as assessed by a PKA
substratemotif antibody, trended (p = 0.053) to be suppressed in
WAT after MBH insulin infusion (Figure S3B). These results
suggest that in addition to suppressing Hsl activity, MBH insulin
reduces Atgl activation by decreasing perilipin phosphorylation
and thereby favoring CGI-58 retention. Thus, brain insulin regu-
lates Hsl activity and likely Atgl activation via PKA.
Insulin antagonizes cAMP signaling through activation of
phosphodiesterase 3B (PDE3B) in an Akt-dependent manner
(Degerman et al., 2003). It has been shown that hypothalamic
leptin signaling can increase insulin signal transduction as as-
sessed by Akt phosphorylation in peripheral organs like the liver
(German et al., 2009). Both leptin and insulin regulate autonomic
outflow within the MBH (Buettner and Camacho, 2008), which
could influence insulin signaling—through crosstalk from cAMP
signaling, for example. Although we controlled circulating insulin
levels during the clamp studies, it is still conceivable that hypo-
thalamic insulin could enhance insulin signaling in WAT. Thus,
we tested whether MBH insulin alters Akt activation in WAT as
assessed by Akt phosphorylation at Ser473. We found that
MBH insulin did not change Akt phosphorylation in WAT (Fig-
ure S3C), indicating that the effects of brain insulin on WAT
metabolism occur independently of changes in peripheral insulin
signaling.
Brain Insulin Induces Lipogenesis in WAT
Lipogenesis in WAT has recently been shown to regulate whole-
body insulin sensitivity by generating palmitoleate, which
improves insulin sensitivity (Cao et al., 2008). Furthermore, we
have found that lipogenesis in WAT is upregulated in metaboli-
cally beneficial states, even though adiposity is decreased. For
example, lipogenesis is elevated in young versus aged rats (Fig-
ure S3D), calorically restricted (CR) aged rats versus ad libitum
(AL) fed aged rats (Figure S3D), and exercised versus sedentary
mice (data not shown). Since hyperinsulinemia induces lipogen-
esis in WAT (Assimacopoulos-Jeannet et al., 1995), we asked if
brain insulin signaling is sufficient to increase lipogenesis in
WAT in the absence of peripheral hyperinsulinemia and assessed
lipogenic protein expression in the same tissue lysates that had
been used for the Hsl western blot analysis (Figure 3A). MBH
insulin increased the expression of the key lipogenic proteins
fatty acid synthase (FAS, encoded by Fasn) and acetyl-CoA
carboxylase (Acc, encodedbyAcaca) (Figure 3B). Adipose tissue
FAS enzyme activity of MBH insulin-infused rats was increased
by 60%, just below statistical significance (p = 0.086) (Figure 3D).
Protein expression of ATP-citrate lyase (Atpcl) and its phosphor-
ylation, a marker of the activated state, trended to be increased
(Figure 3B). These findings implicate that, in vivo, (1) WAT lipo-
genesis and lipolysis are inversely regulated by hypothalamic
insulin, and (2) MBH insulin seems to oppose the acute actions
of MBH leptin. We have shown in a prior study that MBH leptin
induces lipolysis and inhibits lipogenesis by increasing sympa-
thetic outflow to WAT (Buettner et al., 2008).Cell MMBH Insulin Dampens SNS Activity
Therefore, to delineate whether the effects of MBH insulin
on WAT metabolism are mediated via the autonomic nervous
system, we performed surgical denervation as well as phar-
macological sympathectomy of rat epigonadal fat pads using
6-hydroxydopamine (6-OHDA). Both surgical denervation and
pharmacological sympathectomy suppressed basal WAT Hsl
activation, a marker for sympathetic outflow to WAT (Bartness
et al., 2010; Buettner et al., 2008). This effect was replicated
with MBH insulin infusion (Figure 4A). Although this experiment
is not an ultimate proof of a linear pathway, these data suggest
that hypothalamic insulin regulates Hsl activation via suppres-
sion of SNS outflow to WAT.
The Acute Inhibition of Brain Insulin Signaling
Is Sufficient to Unrestrain Lipolysis
We next asked if the acute induction of brain insulin resistance is
sufficient to alter lipolysis. S961 is a recently identified peptide
inhibitor that blocks insulin binding to the insulin receptor, while
not inhibiting insulin or insulin-like growth factor (IGF)-1 binding
to the IGF receptor or IGF-1 binding to the insulin receptor
(Scha¨ffer et al., 2008). First, we validated that S961 blocked
insulin-induced insulin receptor phosphorylation in the MBH
after i.c.v. infusion (Figures 4B), which also obliterated down-
stream signaling (Figure S4A). To assess if the inhibition of
endogenous insulin in the MBH is sufficient to unrestrain lipol-
ysis, we infused either the insulin receptor antagonist S961 or
vehicle into male SD rats for 4 hr, while simultaneously infusing
[2H-5]glycerol tracer systemically (Figure 4C). During the infusion
study, systemic glucose and insulin levels were similar between
groups (Figures S4B and S4C). Indeed, inhibiting endogenous
insulin signaling in the MBH doubled the Ra glycerol (Figure 4D),
suggesting that hypothalamic insulin resistance can contribute
to the unrestrained lipolysis seen in the insulin-resistant state.
Since increased GP is a major component of widespread SNS
activity (Gellhorn, 1954) and glucose levels throughout the entire
infusion experiment were not different in S961 versus vehicle-
infused rats, it is unlikely that S961 is an unspecific activator of
the SNS.
The denervation studies shown in Figure 4A suggested that
MBH insulin reduces WAT lipolysis via the autonomic nervous
system, since MBH insulin suppressed Hsl phosphorylation,
comparable to chemical sympathectomy. Here, we further
tested this concept by asking if the unrestrained lipolysis
induced by the acute inhibition of insulin signaling in theMBHde-
pended on intact sympathetic innervations. To this end, we
induced systemic sympathectomy in male SD rats by injecting
6-OHDA. After a short recovery period, we subjected the animals
to the same infusion studies depicted in Figure 4C in order to test
if MBH S961 would still be able to increase Ra glycerol. As
expected, systemic sympathectomy obliterated the prolipolytic
effects of the insulin antagonist (Figure 4E). Importantly, WAT
norepinephrine (NE) content was markedly reduced, verifying
the sympathectomy (Figure 4F). Ra glycerol trended to be lower
in the denervated animals compared to sham controls, suggest-
ing that sympathectomy lowers prolipolytic input to WAT. Thus,
these results provide further support for the concept that MBH
insulin signaling controls WAT lipolysis by dampening SNS
activity.etabolism 13, 183–194, February 2, 2011 ª2011 Elsevier Inc. 187
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Figure 4. Acute Inhibition of Endogenous MBH Insulin Signaling Is Sufficient to Unrestrain Lipolysis in WAT, which Depends on Sympathetic
Innervations
(A) MBH insulin suppresses Hsl activation to a degree similar to surgical denervation or selective pharmacological sympathectomy of the epidydimal fat pad,
indicating that insulin suppresses lipolysis through a reduction of sympathetic nervous system outflow to WAT. Left, quantifications; right, western blot analyses
(nR 3 per group).
(B) Validation of the insulin receptor antagonist in vivo. S961 was coinfused with insulin in equimolar amounts into the i.c.v. of male SD rats. S961 blocked insulin-
induced MBH insulin receptor phosphorylation (n = 3 per group).
(C) Schematic study outline. Male SD rats were infused with glycerol tracer and received either vehicle or S961 for 4 hr into the MBH.
(D) Ra glycerol of MBH vehicle- and S961-infused rats as per protocol depicted in Figure 4C (nR 4 per group).
(E) Ra glycerol of sham and pharmacologically sympathectomized rats that were infused with either MBHS961 or vehicle. A protocol similar to that depicted in (C)
was used (nR 6 per group).
(F) WATNE levels in sham versus 6-OHDA denervated rats (n = 4 per group). All error bars are SEM; *p < 0.05, **p < 0.01 versus vehicle group. ###p < 0.001 versus
i.c.v. vehicle and i.c.v. insulin + S961 group (see also Figure S4).
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Brain Insulin Controls Adipose Tissue FunctionGenetic Deletion of the Neuronal Insulin Receptor
Increases Lipolysis in Mice and Impairs the Metabolic
Switch from Fasting to Refeeding
To test if neuronal insulin signaling mediates the role of
brain insulin in regulating lipolysis, we studied glycerol fluxes
in neuronal insulin receptor knockout (NIRKO) and littermate
lox-lox control mice (Figure S5A) during hyperinsulinemic-eugly-
cemic clamp studies (Figures S5B and S5C, protocol depicted in
Figure 5A). NIRKOmice have been reported to be susceptible to
diet-induced obesity, although their body weight (BW) is not188 Cell Metabolism 13, 183–194, February 2, 2011 ª2011 Elsevier Inaltered when they are young and fed a standard chow diet.
Furthermore, they develop mild insulin resistance when they
get older than 6 months (Bru¨ning et al., 2000). We find that
4-month-old NIRKOmice required equal GIR during a hyperinsu-
linemic clamp, indicating no or only mild impairment of glucose
homeostasis in young NIRKO mice (Figure S5D). In the fasted
state, NIRKO mice exhibited a 2-fold higher Ra glycerol
compared to lox-lox littermate controls (Figure 5B), although
insulin levels were not different (Table S1), demonstrating that
neuronal insulin signaling controls basal lipolytic rate. Inductionc.
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Figure 5. Genetic Disruption of Neuronal
Insulin Signaling Increases Whole-Body
Lipolytic Flux and Impairs the Switch from
Fasting to Refeeding
(A) Schematic representation of the clamp studies
in NIRKO mice. Following a 16 hr fast, NIRKO and
littermate control mice were subjected to
a 110 min 4 mU $ kg1 $ min1 hyperinsulinemic-
euglycemic clamp study.
(B) Baseline and clamp glycerol fluxes as assessed
by [2H-5]glycerol tracer infusion are increased in
the NIRKO mice (nR 5 per group).
(C) Plasma b-hydroxybutyrate levels are elevated
in the NIRKO mice following a 16 hr fasting chal-
lenge (n = 9 per group).
(D) Depiction of the fasting-refeeding protocol.
(E) Plasma insulin before and after refeeding (nR 8
per group).
(F) Plasma NEFA levels before and after refeeding.
Insert depicts percent suppression of plasma
NEFA levels after food intake (nR 7 per group).
(G) Food intake during refeeding (nR 9 per group).
(H) Bodyweights after fasting (nR 9 per group). All
error bars are SEM; *p < 0.05 versus littermate
control mice (see also Figure S5 and Table S1).
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clamp raised insulin levels equally in both groups (Figure S5B),
and while glycerol fluxes were suppressed in both NIRKO and
control mice (presumably through the direct actions of insulin
on adipocytes), the Ra glycerol remained higher in the NIRKO
mice (Figure 5B) while glucose and glucagon levels were not
different between groups (Figures S5C and Table S1). These
data indicate that lipolytic flux is exquisitely sensitive to brain
insulin action, more so than hepatic glucose fluxes. Changes in
levels of plasma NEFA and glycerol did not show significant
differences (Figure S5E). Since unrestrained lipolysis is expected
to increase ketogenic substrate flux to the liver, we further
assessed whether NIRKO mice display increased ketogenesis.
Indeed, NIRKO mice challenged with a 16 hr fast had elevated
b-hydroxybutyrate levels compared to control animals (Fig-
ure 5C), supporting the concept that brain insulin signaling can
regulate both lipolysis and ketogenesis. Plasma NEFA and
glycerol levels were not different between groups following the
16 hr fast (Figures S5F and S5G). The transition from fasting to
refeeding is a physiological challenge that requires adipose
tissue to readily switch from NEFA release to NEFA retention.
To assess the role of neuronal insulin receptor signaling in this
metabolic adaptation, we fasted NIRKO and control littermates
overnight and then refed them during the onset of their feeding
cycle (protocol depicted in Figure 5D). This allowed us to assess
the suppression of NEFA release after refeeding. While fasting
NEFAs were not different between NIRKO and control mice,Cell Metabolism 13, 183–194, February 2, 2011 ª2011 Elsevier Inc. 189r
,
)
r
,
tthe suppression of NEFAs following a 2 hr
refeeding period in NIRKO mice was
significantly lower (Figure 5F), despite
higher peripheral insulin levels after
feeding (Figure 5E). Insulin levels of
control mice were unchanged after
feeding, which is consistent with prioreports that showed that lean insulin-sensitive C57BL/6 mice
do not exhibit a change in insulin levels after oral glucose admin-
istration (Andrikopoulos et al., 2008). Bodyweights and food
intake during refeeding were not different between groups
(Figures 5G and 5H). These data indicate that the neuronal insulin
receptor regulates lipolysis in WAT during the fasting-to-feeding
transition.
Neuronal Insulin Receptor Signaling Regulates
De Novo Lipogenesis in WAT
Consistent with our findings from the rat studies where MBH
insulin increased lipogenic protein expression, loss of brain
insulin signaling in the NIRKO mice decreased Acc and FAS
protein expression as well as activated phospho-Atpcl in WAT
under clamped and overnight-fasted conditions (Figures 6A
and S5H), suggesting that the lifelong absence of brain insulin
signaling disrupts WAT lipogenesis. To test whether the
decreased WAT lipogenic enzyme expression in the NIRKO
mice translated into alterations in WAT fatty acid composition
we generated fatty acid lipid profiles from epidydimal fat pads
of fasted control and NIRKO mice. We found a marked suppres-
sion of several fatty acid species (14:0, 14:1n5, 16:0, 16:1n7
associated with de novo lipogenesis in the epidydimal fat depots
of the NIRKO mice (Figure 6C), as well as a lower de novo
lipogenesis index (Figure 6B), which is used as a marker fo
lipogenesis (Chong et al., 2008; Hudgins et al., 1996). However
oleate (18:1n9) and linoleic acid (18:2n6), two of the mos
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Figure 6. Loss of Neuronal Insulin Receptor
Signaling Impairs De Novo Lipogenesis in
WAT
(A) Left, representative western blot analyses of
lipogenic protein expression and the activation
state of Atpcl in epidydimal fat pads obtained at
the end of the clamp study. Right, quantification
of western blot data compared to littermate control
mice (nR 5 per group).
(B) De novo lipogenesis (DNL) index calculated
using the ratio of palmitic (16:0) to linoleic acid
(18:2n6) (nR 5 per group).
(C) Differences of WAT fatty acid species of over-
night-fasted NIRKO and control mice. Arrowhead
marks palmitoleate (n = 6 per group).
(D) Correlation between the expression of lipo-
genic proteins and palmitoleate levels (n = 11). All
error bars are SEM; *p < 0.05, **p < 0.01 versus
control mice.
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Brain Insulin Controls Adipose Tissue Functionabundant fatty acids inWAT,werenot significantly changed, sug-
gesting that triglyceride content was not different between
groups. Notably, the insulin-sensitizing lipokine palmitoleate
(16:1n7), which is produced during de novo lipogenesis in WAT
(Cao et al., 2008), was decreased in the NIRKOmice (Figure 6C).
Furthermore, palmitoleate levels in WAT correlated closely with
the expression of the lipogenic enzyme Acc and the activation
state of Atpcl in the fasted state, further supporting the notion
that brain insulin regulatespalmitoleate synthesis through regula-
tion of WAT lipogenesis (Figure 6D). These findings assign a
critical role to neuronal insulin signaling inmaintainingWAT func-
tion. We speculate that hypothalamic insulin resistance could
contribute to the decreased lipogenic protein expression in
WATobserved in obesity. This in turn leads to decreasedproduc-
tion of the insulin-sensitizing fatty acid palmitoleate, further wors-
ening systemic insulin resistance.
DISCUSSION
WAT has emerged as a critically important organ for whole-body
glucose and lipid homeostasis. WAT is an important metabolic
sink, clearing and storing circulating lipids, thereby protecting
other organs from ectopic lipid accumulation. In addition, WAT
is an important source of adipokines like leptin and adiponectin,
and inflammatory mediators like TNF-a and IL-6 that circulate190 Cell Metabolism 13, 183–194, February 2, 2011 ª2011 Elsevier Inc.and can impair insulin signaling in distant
organs including thehypothalamus (Zhang
et al., 2008). During fasting, WAT is the
main source of NEFAs that provide energy
substrates to muscle and liver. Unre-
strained lipolysis during the absorptive
state induces lipotoxicity and a low-grade
inflammation that is commonly associated
with obesity and diabetes (Boden, 2006).
Lastly, de novo lipogenesis in WAT
produces insulin-sensitizing fatty acid
species like palmitoleate (Caoet al., 2008).
Our studies establish that neuronal and
in particular hypothalamic insulin action isa critical regulator of WAT metabolism. We demonstrate that
brain insulin action restrains lipolysis by reducing sympathetic
outflow to WAT and controls de novo lipogenesis in adipose
tissue. Impaired brain and hypothalamic insulin signaling
increases lipolytic flux and decreases de novo lipogenesis,
hampering the production of the insulin-sensitizing fatty acid pal-
mitoleate. We come to this conclusion after delineating the role
of brain insulin in regulatingWATmetabolism in two independent
models: (1) SD rats, where we either increased or inhibited brain
or MBH insulin signaling, and (2) mice with a lifelong disruption of
neuronal insulin signaling. The molecular mechanism through
which MBH insulin regulates WAT metabolism within the adipo-
cyte is comprised of an increase in lipogenic protein expression
and activity and a decrease in the activation state of lipolytic
enzymes like Hsl (see proposed model in Figure 7). Whether
other antilipolytic regulators such as adenosine, prostaglandin
E2, neuropeptide Y, or lactate participate in the regulation of
WAT metabolism by brain insulin remains to be determined
(Ahmed et al., 2010; Jaworski et al., 2009; Lafontan and Langin,
2009).
These findings that ascribe a role of brain insulin signaling in
the regulation of WAT functionality not only have implications
for lipid metabolism, but are also likely to be relevant in glucose
homeostasis, since lipolytic flux can contribute to hepatic gluco-
neogenesis (Mittelman and Bergman, 2000; Rebrin et al., 1996).
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Figure 7. Proposed Model of the Role of
Brain Insulin in Regulating WATMetabolism
Insulin inhibits WAT lipolysis through both direct
and indirect effects: insulin binding to the insulin
receptor expressed on adipocytes results in inacti-
vation of PDE3B, leading to the degradation of
cAMP (Degerman et al., 1990; Smith et al., 1991).
We propose that in addition to the direct effects
of insulin on adipocytes, hypothalamic insulin
signaling suppresses lipolysis and induces lipogen-
esis indirectly by dampening SNS outflow to WAT.
The reduction in lipolysis contributes to a decrease
in hepatic GP by limiting the flux of the gluconeo-
genic precursor glycerol andNEFAs,whichprovide
energy substrates for gluconeogenesis.
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Brain Insulin Controls Adipose Tissue FunctionIndeed, our data indicate that lipolytic flux is exquisitely sensitive
to brain insulin action, more so than hepatic glucose fluxes. MBH
insulin infusion in rats did not alter hepatic GP even after 4 hr,
while Ra glycerol flux was already altered. Only after somato-
statin infusions were started did an effect on hepatic GP become
apparent.
There is growing evidence that in obesity and diabetes,
lipogenic capacity of adipose tissue is reduced in rodents as
well as humans (Diraison et al., 2002; Moraes et al., 2003; Nadler
et al., 2000). The stimulatory effects of brain insulin on WAT lipo-
genesis, plus the finding that the absence of the neuronal insulin
receptor impairs the lipogenic capacity of WAT, suggest that the
dysregulation of WAT adipose tissue lipogenesis in obesity is at
least in part a function of brain insulin resistance.
Furthermore, our findings suggest that brain insulin action has
important anabolic function in WAT maintenance, which is inde-
pendent of, but complements, cell-autonomous effects of insulin
on adipocytes. In further support of this concept, a recent study
showed that the presence of the brain insulin receptor is critically
important to prevent lipodystrophy in mice (Koch et al., 2008).
The same study showed that chronic i.c.v. insulin infusion in
mice leads to increased fat pad mass and hypertrophy of adipo-
cytes, which the authors ascribed to increased lipogenesis.
Equally if not more important in the control of adiposity is likely
the regulation of WAT lipolysis through brain insulin signaling.
We draw this conclusion from the finding that denervation of
WAT leads to no change in lipogenic protein expression, but
completely abrogates Hsl activation, leading to increased
adipose depot mass (Buettner et al., 2008). The absence of
WAT renders humans (Hegele, 2003; Petersen et al., 2002) and
mice (Shimomura et al., 1999) severely insulin resistant due toCell Metabolism 13, 183–194the ectopic accumulation of lipids in
tissues such as muscle and liver. Ectopic
lipids impair insulin signaling and induce
a proinflammatory state. In an insulin-
sensitive organism, WAT is metabolically
flexible and able to readily switch from
a fatty acid-storing to a fatty acid-
releasing mode according to metabolic
needs.
Our studies raise several questions.
One is which neuronal subtype within
the CNS and the MBH mediates theeffects of insulin on the regulation of WAT metabolism. Several
neuron-specific insulin receptor knockout models have been
generated (Belgardt et al., 2009), although to our knowledge an
analysis of lipolytic flux or WAT lipogenesis has not been under-
taken as of yet. Judging from the energy balance and glucose
homeostasis phenotype of these diverse models, it appears
that the effects of brain insulin are not explained by a single
neuronal population, but rather through an intricate and currently
poorly understood communication within a complex neuronal
network where, in some instances, insulin signaling in one
neuron type can even antagonize the effects of insulin signaling
in another neuronal population (Lin et al., 2010). Thus, even if
a specific neuronal KO of the insulin receptor abolishes the ability
of brain insulin to regulate WAT metabolism, this may mean that
a certain balance within this neuronal network is disturbed, not
that this particular neuron population is the chief target and
mediator of hypothalamic insulin action. Another question is
whether brain insulin signaling or adipocyte insulin signaling is
predominant in the regulation of WAT metabolism by systemic
insulin. Our studies clearly establish that in the absence of alter-
ations of circulating insulin levels, brain insulin action plays a crit-
ical role in the regulation of WAT metabolism.
Furthermore, our findings raise the possibility that hypotha-
lamic insulin action may either (1) regulate both lipolysis and
hepatic GP via a suppression of sympathetic outflow to the liver
or (2) indirectly regulate hepatic GP by decreasing the flux of
glycerol andNEFA to the liver via suppression of lipolysis inWAT.
Finally, conditions in which brain insulin signaling is compro-
mised, such as high-fat feeding (Ono et al., 2008), chronic inflam-
matory conditions (Zhang et al., 2008), and obesity (Posey et al.,
2009; Zhang et al., 2008), are likely to dysregulate the control of, February 2, 2011 ª2011 Elsevier Inc. 191
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Brain Insulin Controls Adipose Tissue Functionlipolysis and de novo lipogenesis in WAT due to impaired insulin
action in the hypothalamus. Thus, hypothalamic insulin resis-
tance unrestrains lipolysis and reduces the lipogenic capacity
in WAT, which in turn induces lipotoxicity, resulting in peripheral
insulin resistance and thereby perpetuating a vicious cycle.
EXPERIMENTAL PROCEDURES
Animals
Rat experiments were performed in standard-chow-fed (Rodent Diet 5001,
LabDiet, St. Louis) male SD rats (Charles River Breeding Laboratories,
Wilmington, MA) housed in a temperature- and light-controlled facility in sepa-
rate cages. Prior to the clamp studies, rats were stereotactically fit with
indwelling cannulae targeting the third ventricle (i.c.v.) or theMBH (see Supple-
mental Experimental Procedures). After a 1 week recovery period, carotid and
jugular catheters were implanted for blood sampling and infusion, respec-
tively. Rats were allowed to recover for an additional 4 days and required to
return to within 10% of their presurgical BW.
NIRKO mice were generated as described elsewhere (Bru¨ning et al., 2000;
Fisher et al., 2005), housed on a 12 hr light-dark cycle, and fed a standard
rodent diet (Mouse Diet 9F, PMI Nutrition International, St. Louis). All animal
protocols were approved by the IACUC of Mount Sinai School of Medicine.
Rat Pancreatic Clamp Studies
Rat clamp experiments were performed in 10-week-old, conscious, nonre-
strained, and ad libitum-fed male SD rats. An i.c.v. (5 ml/hr) or MBH (0.18 ml/hr
per side) infusion with either vehicle (artificial cerebrospinal fluid [aCSF];
Harvard Apparatus, Holliston, MA) or insulin (i.c.v., 30 mU;MBH, 2 mU; Humulin
R, Lilly) was started and maintained for 360 min. [3-3H]glucose and [2H-5]glyc-
erol tracers were infused as depicted in Figure 1A. The insulin clamp was initi-
ated with a primed continuous infusion of insulin (1 mU or 3 mU $ kg1 $min1
infusion; Humulin R, Lilly) while also infusing somatostatin (3 mg $ kg1 $min1).
We collected plasma samples before and at the end of the clamp to determine
Ra glycerol during baseline and clamped period. See Supplemental Experi-
mental Procedures for a more detailed description.
Local Denervation Experiment
Epidydimal fat pads were denervated as previously described (Buettner et al.,
2008). Rats were infused for 4 hr with either MBH insulin (1.44 mU) or aCSF
(vehicle). See Supplemental Experimental Procedures for a more detailed
description.
Insulin Antagonist Infusion Experiment
Eight-week-old male SD rats were equipped with MBH cannulae and cathe-
ters. Rats were infused for 4 hr with either aCSF (vehicle) or 0.1 pmoles of
the insulin receptor antagonist S961 (a gift from Novo Nordisk, Maaloev,
Denmark) (Scha¨ffer et al., 2008) into the MBH, while also employing a [2H-5]
glycerol tracer infusion.
Systemic Pharmacological Sympathectomy Experiment
Eight-week-old male SD rats were simultaneously implanted with MBH
cannulae and jugular catheters during ketamine-xylazine anesthesia. After a
3 day recovery period, rats were given two IV bolus injections of 6-OHDA or
vehicle (0.9% saline containing 0.1% ascorbic acid) 3 days apart (50 mg/kg
BW freshly prepared in 0.9% saline containing 0.1% ascorbic acid). Vehicle-
injected animals were pair-fed to 6-OHDA-injected rats to match their BWs.
Three days following the last IV injection, rats were either infused with
MBH vehicle (aCSF) or S961 (0.1 pmoles) using the protocol depicted in Fig-
ure 4C. After 2 hr, a [2H-5]glycerol tracer infusion was started and maintained
(30 mmol $ kg1 $ min1 for 4 min bolus followed by 3 mmol $ kg1 $ min1) for
2 hr. Blood samples for Ra glycerol analysis were taken at time point (TP)
240 min by tail vein sampling. Only rats recovered within 10% of their presur-
gical BW were used.
Mouse Clamp Experiments
Mouse clamp studies were performed in 16 hr fasted, 4-month-old, male,
conscious, nonrestrained NIRKO and littermate lox-lox control mice that192 Cell Metabolism 13, 183–194, February 2, 2011 ª2011 Elsevier Inwere equipped with femoral artery and right jugular vein catheters. Surgical
details are described in Supplemental Experimental Procedures. The protocol
consisted of a 100 min tracer equilibration period followed by 110 min clamp
period as depicted in Figure 5A. A 10 mmol bolus of [2H-5]glycerol (98 atom
percent excess) was given at t = 100 min, followed by a continuous infusion
at 4 mmol $ kg1 $ min1 over 210 min. The insulin clamp was initiated at t =
0min with a continuous infusion of human insulin (4mU $ kg1 $min1 infusion;
Humulin R, Lilly) lasting 110 min. Euglycemia was maintained by measuring
glucose every 10 min and infusing 50% dextrose as necessary. Plasma
samples were collected before and at the end of the clamp to determine Ra
glycerol during baseline and clamped period, respectively. To minimize blood
loss, we reinfused spun-down erythrocytes, which were resuspended in
saline.Mouse Fasting-Refeeding Experiments
Ten-week-old NIRKO and littermate control mice were fasted for 24 hr starting
at 3 p.m. the day before the experiment, so the refeeding period coincided with
the onset of the feeding cycle (protocol depicted in Figure 5D). An initial blood
sample was taken from the tail vein at TP 0 min. After 90 min, mice were
granted ad libitum access to regular chow food for 2 hr. The final blood sample
(TP 210 min) was obtained by tail.Analytic Procedures
Prior to tissue analyzes, animals were anesthetized and killed and their tissues
were snap frozen in liquid nitrogen. Blood was collected in EDTA tubes, and
glucose was measured by Freestyle Freedom glucose analyzer (Abbot, Abott
Park, IL). We analyzed glucose fluxes and Ra glycerol as described elsewhere
(Kang et al., 2007; Liu et al., 1998; Obici et al., 2002; Pocai et al., 2005). Plasma
metabolite assays, WAT NE measurements, and tracer methodology details
are described in Supplemental Experimental Procedures.FAS Activity
FAS activity in perirenal fat was measured spectrophotometrically using
a modified protocol of Nepokroeff et al. (1975). Detailed description can be
found in Supplemental Experimental Procedures.Triglyceride Hydrolase Activity
Assay was performed with epidydimal fat pads as previously described
(Schweiger et al., 2006). Cytosolic and lipid droplet fraction from rat adipose
tissue were obtained using a modified protocol of Schweiger et al. (2008).
Detailed description can be found in Supplemental Experimental Procedures.Fatty Acid Analysis
Fatty acid analysis was performed as previously described (Scheja et al.,
2008). Detailed description can be found in Supplemental Experimental
Procedures.RNA Extraction and Quantitative Real-Time RT-PCR
Detailed description and forward and reverse customized primer pairs (Invitro-
gen, Carlsbad, CA) are described in Supplemental Experimental Procedures.Western Blot Analyses
Western blots were performed as previously described (Buettner et al., 2008).
Detailed description and antibodies used can be found in Supplemental
Experimental Procedures.Statistics
All data are represented as mean ± SEM. Comparisons among groups were
made using one-way ANOVA followed by unpaired two-tailed Student’s t tests
if not otherwise indicated. Differences were considered statistically significant
at p < 0.05. For Figures 2F, 6D, S2H, and S2I, we used Pearson correlation and
a two-tailed t test performed in GraphPad Prism 5.0b for Mac (GraphPad Soft-
ware, San Diego, CA).c.
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Supplemental Information includes Supplemental Experimental Procedures,
Supplemental References, five figures, and one table and can be found with
this article online at doi:10.1016/j.cmet.2011.01.008.
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